Core Points - The company, Nanjing Pharmaceutical Co., Ltd., announced the second extraordinary general meeting of shareholders for 2025, scheduled for November 19, 2025 [1] - The meeting will utilize a combination of on-site and online voting methods [1][2] - The company will remind small and medium-sized investors to participate in the voting through SMS notifications [6] Meeting Details - Meeting Date: November 19, 2025, at 14:00 [1] - Location: Conference Room, 8th Floor, Building 2, No. 55, Andemen Street, Yuhuatai District, Nanjing [1] - Voting Methods: On-site voting and online voting via the Shanghai Stock Exchange system [1][2] Voting Procedures - Online voting will be available on the day of the meeting from 9:15 to 15:00 [2] - Shareholders can vote through the trading system or the internet voting platform [5] - Multiple accounts held by a shareholder will allow them to aggregate their voting rights [6] Agenda Items - The meeting will review several proposals, including special resolutions and separate voting for small and medium-sized investors [5] - The proposals were previously approved by the board on October 29, 2025 [4] Attendance - Eligible attendees include shareholders registered by the close of trading on the registration date, company directors, supervisors, and appointed lawyers [10] - Registration for attendance will occur on November 18, 2025 [12][13] Financial Management - The company approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk financial products [17] - A specific investment of 60 million yuan in a structured deposit product yielded a return of 247,200 yuan upon redemption [18]

南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于 2025 年 1 月 20-22 日召开 第九届董事会临时会议及第九届监事会临时会议，审议通过了《关于公司及子公 司使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不 超过 7 亿元（含本数）暂时闲置募集资金进行现金管理，投资的产品品种为安全 性较高、流动性较好、风险较低的保本型理财产品。使用期限自公司董事会审议 通过之日起 12 个月内有效，上述额度在使用期限内可以滚动使用，到期后归还 至募集资金专户。详情请见公司于2025年1月23日对外披露的编号为ls2025-007 之《南京医药股份有限公司关于公司及子公司使用部分暂时闲置募集资金进行现 金管理的公告》。 一、本次使用部分暂时闲置募集资金进行现金管理到期赎回情况 2025 年 8 月 8 日，公司子公司福建同春药业股份有限公司（以下简称"福 建同春"）使用部分暂时闲置募集资 ...

| 证券代码：600713 | 证券简称：南京医药 | 公告编号：ls2025-138 | | --- | --- | --- | | 债券代码：110098 | 债券简称：南药转债 | | 南京医药股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于 2025 年 10 月 31 日发布《南 京医药股份有限公司关于召开 2025 年第二次临时股东大会的通知》，上述公告 已刊登在《中国证券报》、《上海证券报》以及上海证券交易所网站 （www.sse.com.cn）。根据相关规定，公司现发布本次股东大会的提示性公告如 下： 重要内容提示： 一、 召开会议的基本情况 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 19 日 14 点 00 分 召开地点：南京市雨花台区安德门大街 55 号 2 幢 8 层会议室 (五) ...

南京医药股份有限公司 2025 年第二次临时股东大会材料 2025 年 11 月 19 日 目 录 | 南京医药股份有限公司 2025 年第二次临时股东大会议程 2 | | --- | | 议案一：关于修订《南京医药股份有限公司章程》相关条款并取消监事会、 | | 变更公司全称及注册资本的议案 4 | | 议案二：关于修订《南京医药股份有限公司股东大会议事规则》相关条款 | | 的议案 74 | | 议案三：关于修订《南京医药股份有限公司董事会议事规则》相关条款的 | | 议案 92 | | 议案四：关于修订《南京医药股份有限公司企业负责人薪酬与绩效考核管 | | 理办法》的议案 108 | | 议案五：关于增补第十届董事会非独立董事的议案 127 | 1 南京医药股份有限公司 2025 年第二次临时股东大会议程 一、介绍参会的嘉宾和股东情况 二、宣读会议审议的议案相关内容 1、审议关于修订《南京医药股份有限公司章程》相关条款并取消监 事会、变更公司全称及注册资本的议案； 2、审议关于修订《南京医药股份有限公司股东大会议事规则》相关 条款的议案； 3、审议关于修订《南京医药股份有限公司董事会议事规则》相关条 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-137 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于控股股东减持公司可转换公司债券的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于近日收到控股股东南京新工投 资集团有限责任公司（以下简称"新工投资集团"）的通知，新工投资集团已于 2025 年 10 月 16 日至 2025 年 11 月 4 日期间继续通过上海证券交易所（以下简称 "上交所"）系统减持其持有的部分公司可转换公司债券（以下简称"可转债"）。 现将具体情况公告如下： 一、控股股东配售可转债情况 经中国证券监督管理委员会《关于同意南京医药股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2024〕1736 号）核准，公司向不特 定对象发行可转债 10,814,910 张，每张面值为人民币 100 元（人民币，下同），发 行总额 108,149.10 万元。本次发行的可转债存续期限为自发行之日起六年（2024 ...

格隆汇11月5日丨南京医药(600713.SH)公布，公司于近日收到新工投资集团的通知，其已于2025年10月 16日至2025年11月4日期间继续通过上交所系统累计减持"南药转债"110.04万张，占可转债发行总量的 10.17%。 ...

Core Insights - Nanjing Pharmaceutical (600713) reported a slight increase in revenue but a decline in net profit for Q3 2025, indicating challenges in profitability despite stable sales growth [1] Financial Performance - Total revenue for Q3 2025 reached 41.135 billion yuan, a year-on-year increase of 0.48% [1] - Net profit attributable to shareholders was 402 million yuan, down 9.03% year-on-year [1] - In Q3 2025, total revenue was 13.168 billion yuan, reflecting a decrease of 3.93% compared to the same quarter last year [1] - Q3 net profit attributable to shareholders was 111 million yuan, a decline of 15.22% year-on-year [1] Profitability Metrics - Gross margin stood at 5.95%, a decrease of 3.5% year-on-year [1] - Net margin was 1.29%, down 6.49% year-on-year [1] - Total selling, administrative, and financial expenses amounted to 1.546 billion yuan, accounting for 3.76% of revenue, a decrease of 3.4% year-on-year [1] Cash Flow and Assets - Cash flow per share was -3.8 yuan, a significant decrease of 72.03% year-on-year [1] - Cash and cash equivalents increased by 45.98% to 1.692 billion yuan [1] - Accounts receivable decreased by 2.66% to 16.503 billion yuan [1] Debt and Financial Ratios - Interest-bearing debt decreased by 15.69% to 8.404 billion yuan [1] - The company's return on invested capital (ROIC) was 7.08%, indicating average capital returns [4] - The company's debt ratio for interest-bearing liabilities reached 24.69% [4] Business Model and Operational Insights - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying drivers [4] - Historical financial performance has been generally average, with a median ROIC of 8.11% over the past decade [4] - The company has experienced one loss year since its IPO, warranting further investigation into potential causes [4]

Core Points - The company has announced its third-quarter financial report for 2025, which has been approved by the board of directors [29][30]. - The company plans to change its name to "Nanjing Pharmaceutical Group Co., Ltd." and will cancel its supervisory board, transferring its responsibilities to the audit and risk control committee of the board [57][59]. - The company has issued convertible bonds and has begun the conversion process, resulting in an increase in registered capital to 1,308,929,289 shares [60][61]. Financial Data - The company reported a net profit of 0 yuan from merged entities in the current period, consistent with the previous period [26]. - As of the end of the reporting period, the company had a balance of 61.32 billion yuan in accounts receivable factoring without recourse [14]. - The company has issued a total of 15 billion yuan in short-term financing bonds to supplement working capital and repay bank loans [11][12]. Shareholder Information - The company has completed a share buyback program, repurchasing approximately 17.99 million shares, which is 1.38% of the total share capital [9][10]. - The second-largest shareholder, Alliance Healthcare, has transferred its entire stake of 144,557,431 shares, representing 11.04% of the total share capital, to Guangzhou Pharmaceutical Group [18][19]. Corporate Governance - The company has appointed new senior management, including four vice presidents, to align with its strategic goals [24]. - The company will hold its second extraordinary general meeting of 2025 on November 19, 2025, to discuss the proposed changes to the articles of association and other governance matters [41][42]. Investment and Projects - The company has initiated construction on several key projects, including the Fujian Tongchun Biopharmaceutical Industrial Park and the Nanjing Pharmaceutical Central Logistics Center [20][21]. - The company has also engaged in asset disposal, leasing a property for 711.55 million yuan per year for 156 months [22].

Core Viewpoint - Nanjing Pharmaceutical is a well-known enterprise in the domestic pharmaceutical distribution sector, with a comprehensive business model that includes wholesale, retail, and third-party logistics services [1] Group 1: Business Performance - In Q3 2025, Nanjing Pharmaceutical achieved a revenue of 41.135 billion, ranking 5th among 24 companies in the industry, with the industry leader, Shanghai Pharmaceutical, at 215.072 billion [2] - The main business composition includes wholesale at 26.506 billion, accounting for 94.87%, and retail at 1.245 billion, accounting for 4.46% [2] - The net profit for Q3 2025 was 530 million, ranking 9th in the industry, with the top performer, Shanghai Pharmaceutical, at 5.986 billion [2] Group 2: Financial Ratios - As of Q3 2025, Nanjing Pharmaceutical's debt-to-asset ratio was 76.62%, slightly down from 76.75% year-on-year, which is higher than the industry average of 59.74% [3] - The gross profit margin for Q3 2025 was 5.95%, down from 6.16% year-on-year, and below the industry average of 13.11% [3] Group 3: Executive Compensation - The chairman, Zhou Jianjun, received a salary of 1.8182 million in 2024, a decrease of 367,700 from 2023 [4] - The president, Zhang Liang, had a salary of 2.2384 million in 2024, an increase of 134,900 from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.73% to 51,600 [5] - The average number of circulating A-shares held per shareholder increased by 1.77% to 24,900 [5]

Core Viewpoint - Nanjing Pharmaceutical (600713.SH) reported its Q3 2025 results, showing a slight revenue increase but a decline in net profit and non-recurring profit [1] Financial Performance - The company achieved a revenue of 41.135 billion yuan in the first three quarters, representing a year-on-year growth of 0.48% [1] - The net profit attributable to shareholders was 402 million yuan, reflecting a year-on-year decrease of 9.03% [1] - The non-recurring net profit stood at 371 million yuan, down 14.78% year-on-year [1] - Basic earnings per share were reported at 0.31 yuan [1]